[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Capital Junky [@TheCapitalJunky](/creator/twitter/TheCapitalJunky) on x XXX followers Created: 2025-07-18 17:26:57 UTC BiomX's Phase 2b Trial Begins, Analyst Reaffirms $XX Target: Phage Therapy Advances 🚀 $PHGE According to the article, BiomX has initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting lung infections in cystic fibrosis patients. This milestone prompted H.C. Wainwright to reiterate its Buy rating and $XX price target, indicating significant potential upside. The Phase 2b trial is a randomized, double-blind, placebo-controlled study involving approximately XX patients over eight weeks, with topline results expected in Q1 2026. The article highlights the Phase 1b/2a trial results, where XXXX% of patients experienced complete clearance of chronic Pseudomonas aeruginosa infections after ten days, a rare outcome in this patient population. H.C. Wainwright's $XX price target reflects confidence in BiomX's dual-asset approach, equally weighting BX004 (52%) and BX211 for diabetic foot osteomyelitis (48%). The firm's model anticipates an ex-U.S. partnership with a XX% royalty arrangement, with upside catalysts including higher market penetration and expanded indications. The strategic investment of $XX million by the U.S. Defense Health Agency for BX211 further validates the technology and strengthens the investment thesis. BiomX is trying to address unmet medical needs in diabetic foot osteomyelitis and cystic fibrosis, targeting conditions with limited treatment options. $PHGE #wallstwire BiomX Advances with Phase 2b Trial Initiation, Wall Street Analyst Reaffirms $XX Price Target H.C. Wainwright maintains bullish outlook as phage therapy company advances toward pivotal 2026 data readout BiomX Inc. (NYSE: PHGE) reached a significant development milestone this week with the successful initiation of patient dosing in its Phase 2b trial for BX004, a breakthrough phage therapy targeting life-threatening lung infections in cystic fibrosis patients. The achievement prompted H.C. Wainwright to reiterate its Buy rating and $XX price target, representing substantial upside potential from current trading levels around $XXX. The Phase 2b trial marks a pivotal advancement for BiomX’s lead cystic fibrosis program, which has already demonstrated remarkable efficacy in earlier studies. In the company’s Phase 1b/2a trial, XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections after just XX days of treatment, an outcome rarely seen in this patient population, including individuals who had carried infections for over a decade. “This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P. aeruginosa infections who desperately need new options,” said Jonathan Solomon, BiomX’s Chief Executive Officer. The randomized, double-blind, placebo-controlled study will evaluate approximately XX patients over an 8-week treatment period, with topline results expected in the first quarter of 2026. Strong Analyst Support Reflects Growing Confidence H.C. Wainwright’s maintained Buy rating and $XX price target reflects the firm’s confidence in BiomX’s dual-asset approach. The analyst’s valuation model assigns equal weight to the company’s two lead programs: BX004 for cystic fibrosis infections (52% contribution) and BX211 for diabetic foot osteomyelitis (48% contribution). The research firm’s clinical net present value model assumes BiomX will secure an ex-U.S. partner with a XX% royalty arrangement, while identifying multiple upside catalysts including higher market penetration, additional indications, and expanded international opportunities. BX004 has already received significant regulatory support, securing both Fast Track designation and Orphan Drug status from the FDA. These designations provide accelerated review processes and seven years of market exclusivity, potentially streamlining the path to approval for this urgently needed treatment. Military Validation Adds Strategic Value BiomX’s investment thesis extends beyond traditional biotech metrics, bolstered by $XX million in non-dilutive funding previously received from the U.S. Defense Health Agency for its BX211 diabetic foot program. This military backing validates the technology while preserving shareholder value—a significant advantage in an industry typically dependent on dilutive equity financing. The Pentagon’s investment reflects urgent battlefield needs, as CEO Solomon noted that military medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This dual-use application positions BiomX’s phage therapies to address both civilian healthcare crises and national security concerns. Addressing Massive Unmet Medical Needs BiomX’s programs target conditions with enormous unmet medical needs and limited treatment options. For diabetic foot osteomyelitis, no new drugs have been approved in over XX years, despite the condition leading to approximately XXXXXXX amputations annually in the U.S. alone. The company’s successful Phase X DANCE trial demonstrated statistically significant improvements in wound healing, with treated patients showing greater than XX% better outcomes compared to placebo by week XX. In cystic fibrosis, chronic lung infections remain the leading cause of death despite modern treatments. BiomX’s phage cocktail approach offers a fundamentally different mechanism than traditional antibiotics, potentially overcoming resistance issues that limit current therapies. As the global antibiotic resistance crisis intensifies and governments prioritize antimicrobial innovation, BiomX’s validated phage therapy platform positions the company at the forefront of a potential paradigm shift in infectious disease treatment. With analyst price targets suggesting significant upside potential and multiple upcoming catalysts, BiomX represents a compelling opportunity in the evolving biotech landscape. -- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. BiomX or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice.  XXX engagements  **Related Topics** [hc](/topic/hc) [$phge](/topic/$phge) [Post Link](https://x.com/TheCapitalJunky/status/1946260413970038816)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Capital Junky @TheCapitalJunky on x XXX followers
Created: 2025-07-18 17:26:57 UTC
BiomX's Phase 2b Trial Begins, Analyst Reaffirms $XX Target: Phage Therapy Advances 🚀 $PHGE
According to the article, BiomX has initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting lung infections in cystic fibrosis patients. This milestone prompted H.C. Wainwright to reiterate its Buy rating and $XX price target, indicating significant potential upside. The Phase 2b trial is a randomized, double-blind, placebo-controlled study involving approximately XX patients over eight weeks, with topline results expected in Q1 2026.
The article highlights the Phase 1b/2a trial results, where XXXX% of patients experienced complete clearance of chronic Pseudomonas aeruginosa infections after ten days, a rare outcome in this patient population. H.C. Wainwright's $XX price target reflects confidence in BiomX's dual-asset approach, equally weighting BX004 (52%) and BX211 for diabetic foot osteomyelitis (48%). The firm's model anticipates an ex-U.S. partnership with a XX% royalty arrangement, with upside catalysts including higher market penetration and expanded indications. The strategic investment of $XX million by the U.S. Defense Health Agency for BX211 further validates the technology and strengthens the investment thesis. BiomX is trying to address unmet medical needs in diabetic foot osteomyelitis and cystic fibrosis, targeting conditions with limited treatment options. $PHGE
#wallstwire
BiomX Advances with Phase 2b Trial Initiation, Wall Street Analyst Reaffirms $XX Price Target
H.C. Wainwright maintains bullish outlook as phage therapy company advances toward pivotal 2026 data readout BiomX Inc. (NYSE: PHGE) reached a significant development milestone this week with the successful initiation of patient dosing in its Phase 2b trial for BX004, a breakthrough phage therapy targeting life-threatening lung infections in cystic fibrosis patients. The achievement prompted H.C. Wainwright to reiterate its Buy rating and $XX price target, representing substantial upside potential from current trading levels around $XXX.
The Phase 2b trial marks a pivotal advancement for BiomX’s lead cystic fibrosis program, which has already demonstrated remarkable efficacy in earlier studies. In the company’s Phase 1b/2a trial, XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections after just XX days of treatment, an outcome rarely seen in this patient population, including individuals who had carried infections for over a decade.
“This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P. aeruginosa infections who desperately need new options,” said Jonathan Solomon, BiomX’s Chief Executive Officer.
The randomized, double-blind, placebo-controlled study will evaluate approximately XX patients over an 8-week treatment period, with topline results expected in the first quarter of 2026.
Strong Analyst Support Reflects Growing Confidence H.C. Wainwright’s maintained Buy rating and $XX price target reflects the firm’s confidence in BiomX’s dual-asset approach. The analyst’s valuation model assigns equal weight to the company’s two lead programs: BX004 for cystic fibrosis infections (52% contribution) and BX211 for diabetic foot osteomyelitis (48% contribution).
The research firm’s clinical net present value model assumes BiomX will secure an ex-U.S. partner with a XX% royalty arrangement, while identifying multiple upside catalysts including higher market penetration, additional indications, and expanded international opportunities.
BX004 has already received significant regulatory support, securing both Fast Track designation and Orphan Drug status from the FDA. These designations provide accelerated review processes and seven years of market exclusivity, potentially streamlining the path to approval for this urgently needed treatment.
Military Validation Adds Strategic Value BiomX’s investment thesis extends beyond traditional biotech metrics, bolstered by $XX million in non-dilutive funding previously received from the U.S. Defense Health Agency for its BX211 diabetic foot program. This military backing validates the technology while preserving shareholder value—a significant advantage in an industry typically dependent on dilutive equity financing.
The Pentagon’s investment reflects urgent battlefield needs, as CEO Solomon noted that military medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This dual-use application positions BiomX’s phage therapies to address both civilian healthcare crises and national security concerns.
Addressing Massive Unmet Medical Needs BiomX’s programs target conditions with enormous unmet medical needs and limited treatment options. For diabetic foot osteomyelitis, no new drugs have been approved in over XX years, despite the condition leading to approximately XXXXXXX amputations annually in the U.S. alone. The company’s successful Phase X DANCE trial demonstrated statistically significant improvements in wound healing, with treated patients showing greater than XX% better outcomes compared to placebo by week XX.
In cystic fibrosis, chronic lung infections remain the leading cause of death despite modern treatments. BiomX’s phage cocktail approach offers a fundamentally different mechanism than traditional antibiotics, potentially overcoming resistance issues that limit current therapies.
As the global antibiotic resistance crisis intensifies and governments prioritize antimicrobial innovation, BiomX’s validated phage therapy platform positions the company at the forefront of a potential paradigm shift in infectious disease treatment. With analyst price targets suggesting significant upside potential and multiple upcoming catalysts, BiomX represents a compelling opportunity in the evolving biotech landscape.
-- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. BiomX or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice.
XXX engagements
